Le Lézard
Classified in: Science and technology

i2k Connect Reaches Hiring Milestone to deliver Next Generation AI platform


i2k Connect Inc., a global leader in artificial intelligence software, is pleased to announce that it has expanded its team of personnel with four new members.

HOUSTON, March 25, 2023 /PRNewswire-PRWeb/ -- "We welcome new personnel to i2k Connect to bring their different perspectives to solutions for our customer's challenges," said CEO Reid Smith. "The company's membership is particularly relevant as the amount of text and data continues to increase ? both on the web and in proprietary databases. i2k Connect's leadership in creating value from semi-structured and unstructured data benefits customers in several industry sectors and helps them make sense of all that information."

The new team members are Matthew Buchanan, Dylan Holmes, Dalton Hough, and Dhanvanthri Natarajan. Their backgrounds vary from work experience in the financial industry to college majors in philosophy and include two recent Ph.D.'s in computer science. All are working closely with customer representatives to make AI technology immediately useful.

i2k Connect's approach to AI is described in a recent post i2k-ai.com/ChatGPT as focusing on a partnership model in which AI programs use knowledge of a client's subject area in the role of an intelligent assistant. Smith added, "We believe the partnership model offers a way for companies to benefit from AI today. Adding staff helps us deliver immediate value."

About i2k Connect Inc.
i2k Connect's novel Artificial Intelligence technology is informed by industry knowledge. Our platform creates structured data from unstructured documents and delivers analysis-ready results directly to knowledge workers in-cloud or on-premises via a browser or Web API. Learn how i2k Connect® software creates value from unstructured data at http://www.i2kconnect.com.

Media Contact

Becky Thomas, i2k Connect Inc., 1 832-821-0866, [email protected]

Twitter, LinkedIn

 

SOURCE i2k Connect Inc.


These press releases may also interest you

at 12:30
The Integritus Group Inc. Expands Its Portfolio with the Acquisition of LPM Media Group
The Integritus Group., a prominent loss prevention and regulatory compliance firm, announced today the acquisition of LPM Media Group, the industry leading communications company specializing in digital, mobile, and print awareness and e-learning...

at 12:00
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVersetm Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
?  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses?? ? ...

at 11:11
Menswear Brand Highland Duds Introduces The Stack
Direct-to-consumer menswear label, Highland Duds, announces the launch of The Stack: an innovative shopping solution designed to make styling smarter, not harder....

at 09:10
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Notably, Exai's platform maintained...

at 09:05
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
Cyteir Therapeutics, Inc. ("Cyteir") , a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate...

at 09:05
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
Merck , known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment...

More news about Science and technology...


News published on and distributed by: